Johnson & Johnson (J&J) aims to revolutionize bladder cancer treatment with its TAR-200, currently under FDA review. This intravesical system delivers chemotherapy directly into the bladder, targeting Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). Meanwhile, ImmunityBio defends its position with its immunotherapy Anktiva. Both companies presented data at the American Urological Association’s 2025 meeting. J&J reported an 82.4% complete response rate with TAR-200, while ImmunityBio highlighted Anktiva’s long-term response duration of over 45 months. The competition extends to broader NMIBC populations, with both firms exploring additional indications. — new from Fierce Pharma
